VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

Sixiang Shi; Kai Yang; Hao Hong; Feng Chen; Hector F. Valdovinos; Shreya Goel; Todd E. Barnhart; Zhuang Liu; Weibo Cai

doi:10.1016/j.biomaterials.2014.10.061

VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

Sixiang Shi
, Kai Yang
, Hao Hong
, Feng Chen
, Hector F. Valdovinos
, Shreya Goel
, Todd E. Barnhart
, Zhuang Liu
, Weibo Cai

Research output: Journal article publication › Journal article › Academic research › peer-review

71 Citations (Scopus)

Abstract

Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.

Original language	English
Pages (from-to)	39-46
Number of pages	8
Journal	Biomaterials
Volume	39
DOIs	https://doi.org/10.1016/j.biomaterials.2014.10.061
Publication status	Published - Jan 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Graphene oxide (GO)
Positron emission tomography (PET)
Vasculature targeting
VEGF

ASJC Scopus subject areas

Bioengineering
Ceramics and Composites
Biophysics
Biomaterials
Mechanics of Materials

More information

10.1016/j.biomaterials.2014.10.061

Cite this

@article{80fa85a49a2047d59b11fda0c24dd4fb,

title = "VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo",

abstract = "Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 \%ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.",

keywords = "Graphene oxide (GO), Positron emission tomography (PET), Vasculature targeting, VEGF",

author = "Sixiang Shi and Kai Yang and Hao Hong and Feng Chen and Valdovinos, \{Hector F.\} and Shreya Goel and Barnhart, \{Todd E.\} and Zhuang Liu and Weibo Cai",

note = "Funding Information: This work is supported, in part, by the University of Wisconsin–Madison , the National Institutes of Health (NIBIB/NCI 1R01CA169365 and P30CA014520 ), the Department of Defense ( W81XWH-11-1-0644 ), the American Cancer Society ( 125246-RSG-13-099-01-CCE ), the National Basic Research Program of China (973 Program, 2012CB932601 \& 2011CB911002 ), and the National Natural Science Foundation of China ( 51002100 \& 51222203 ). Publisher Copyright: {\textcopyright} 2014 Elsevier Ltd. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.",

year = "2015",

month = jan,

doi = "10.1016/j.biomaterials.2014.10.061",

language = "English",

volume = "39",

pages = "39--46",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

AU - Shi, Sixiang

AU - Yang, Kai

AU - Hong, Hao

AU - Chen, Feng

AU - Valdovinos, Hector F.

AU - Goel, Shreya

AU - Barnhart, Todd E.

AU - Liu, Zhuang

AU - Cai, Weibo

N1 - Funding Information: This work is supported, in part, by the University of Wisconsin–Madison , the National Institutes of Health (NIBIB/NCI 1R01CA169365 and P30CA014520 ), the Department of Defense ( W81XWH-11-1-0644 ), the American Cancer Society ( 125246-RSG-13-099-01-CCE ), the National Basic Research Program of China (973 Program, 2012CB932601 & 2011CB911002 ), and the National Natural Science Foundation of China ( 51002100 & 51222203 ). Publisher Copyright: © 2014 Elsevier Ltd. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.

PY - 2015/1

Y1 - 2015/1

N2 - Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.

AB - Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.

KW - Graphene oxide (GO)

KW - Positron emission tomography (PET)

KW - Vasculature targeting

KW - VEGF

UR - https://www.scopus.com/pages/publications/84919468821

U2 - 10.1016/j.biomaterials.2014.10.061

DO - 10.1016/j.biomaterials.2014.10.061

M3 - Journal article

C2 - 25477170

AN - SCOPUS:84919468821

SN - 0142-9612

VL - 39

SP - 39

EP - 46

JO - Biomaterials

JF - Biomaterials

ER -

VEGFR targeting leads to significantly enhanced tumor uptake of nanographene oxide invivo

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

More information

Other files and links

Fingerprint

Cite this